Starving Tumors of Important Amino Acid May Extend Survival in Pancreatic Cancer

Ariela Katz
Published: Monday, Oct 08, 2018
Manuel Hidalgo, MD, PhD

Manuel Hidalgo, MD, PhD
Investigators are evaluating whether eryaspase (Graspa), an L-asparaginase-based therapy that triggers tumor cell death, can extend survival for patients with pancreatic cancer. Patients with advanced pancreatic adenocarcinoma have few effective treatment options outside of a clinical trial or palliative care,1 and this could solve an unmet medical need.


Figure. Eryaspase in Patients With Advanced Pancreatic Cancer

Eryaspase in Patients With Advanced Pancreatic Cancer

“The beautiful thing about the trial is that eryaspase can be given with either gemcitabine/abraxane- or irinotecan-based chemotherapy, which means that it could be more broadly applicable to the patient population,” Hidalgo said.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication